



Tumor microenvironment noise-induced polarization: the main challenge in macrophages' immunotherapy for cancer

Jesus Sierra¹ · Ugo Avila-Ponce de León² · Pablo Padilla-Longoria³

Received: 2 October 2024 / Accepted: 4 January 2025 / Published online: 19 January 2025
© The Author(s) 2025

Abstract

Disturbance of epigenetic processes can lead to altered gene function and malignant cellular transformation. In particular, changes in the epigenetic landscape are a central topic in cancer biology. The initiation and progression of cancer are now recognized to involve both epigenetic and genetic alterations. In this paper, we study the epigenetic mechanism (related to the tumor microenvironment) responsible for increasing tumor-associated macrophages that promote the occurrence and metastasis of tumor cells, support tumor angiogenesis, inhibit T-cell-mediated anti-tumor immune response, and lead to tumor progression. We show that the tumor benefits from the macrophages' high degree of plasticity and larger epigenetic basins corresponding to phenotypes that favor cancer development through a process that we call noise-induced polarization. Moreover, we propose a mechanism to promote the appropriate epigenetic stability for immunotherapies involving macrophages, which includes p53 and APR-246 (eprenetapopt). Our results show that a combination therapy may be necessary to ensure the proper epigenetic stability of macrophages, which otherwise will contribute to cancer progression. On the other hand, we conclude that macrophages may remain in the anti-tumoral state in types of cancer that exhibit less TP53 mutation, like colorectal cancer; in these cases, macrophages' immunotherapy may be more suitable. We finally mention the relevance of the epigenetic potential (Waddington's landscape) as the backbone for our study, which encapsulates the biological information of the system.

Keywords Cancer immunology · Tumor Microenvironment · Epigenetics · Macrophage polarization · Random perturbations

Introduction

The tumor microenvironment (TME) supplies a fundamental ecological niche for cancer initiation and development. Although there is considerable diversity in the inflammatory components of the TME in cancers from different tissues,

the common denominator is the infiltration of monocytes, macrophages, and dendritic cells [1]. Macrophages are particularly interesting to study from a stochastic analysis point of view due to their plasticity in response to environmental signals. The functional differences of macrophages are closely related to their plasticity. Moreover, molecules in TMEs are responsible for regulating macrophages' functional phenotypes [2]. Such molecular signals are so diverse and random that we consider it fit to treat them as Gaussian noise that increases in magnitude as the tumor progresses. Under this assumption, our mathematical model shows that most tumor-associated macrophages (TAMs) get eventually polarized into macrophages with phenotypes that favor cancer development (these phenotypes have the largest epigenetic basins); this result agrees with the observation in [3] of adverse effects of TAMs on overall survival of patients with gastric, breast, bladder, ovarian, oral, and thyroid cancers, except for positive outcome in patients with colorectal cancer. The latter result may indicate the influence of p53

✉ Pablo Padilla-Longoria
pablo@mym.iimas.unam.mx

Jesus Sierra
jesus.sierra@cimat.mx

Ugo Avila-Ponce de León
uavilapo@fredhutch.org

¹ CIMAT, De Jalisco s/n, Gto., 36023 Guanajuato, Mexico

² Schiffer Group, Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

³ IIMAS, Universidad Nacional Autónoma de México (UNAM), Ciudad Universitaria, 04510 Mexico City, Mexico

on macrophages: in [4], 40–60% of colorectal cancer tumors show TP53 mutation, whereas in ovary cancer, it is 90%. We will discuss later the relevance of p53 on immunotherapies involving macrophages.

Our model shows that the time required for noise-induced polarization of macrophages depends on the noise's magnitude. Hence, we should have fewer macrophages with pro-tumoral features in the early stages of cancer or in situations where the noise associated with the TME is weaker; this may explain why in [5], macrophages in early-stage human lung cancer did not exert immunosuppressive functions.

Finally, we mention that we consider p53 mainly due to the results and observations we gathered from the literature; however, we emphasize that other epigenetic stabilizers could be explored.

Materials and methods

Network reconstruction, boolean states, and epigenetic landscape

We start our analysis by considering a concise network of the molecular basis of macrophage polarization and the Boolean attractors obtained from it. Both sources of data were previously reported in [6, 7]. Our reconstructed network was obtained through a bottom-up approach, where we set up the signaling network by literature research on interactions (see Table 1). This reconstruction resulted in a transcriptional regulatory network (TRN) which included two parts: the extracellular component (cytokines, chemokines and metabolic byproduct present in a tumor microenvironment) and the intracellular component (the master transcription factors (TF) implicated in macrophage polarization). We simulated the dynamics of our TRN using a Boolean approach. Then, Boolean attractors obtained from this network were classified into two main groups: pure (experimentally proven macrophages) or hybrid states (hypothesized phenotype found using boolean models and artificial intelligence [6–8]). In global terms, we used the following basis to label the attractors found in our simulation. For the M1 macrophages, we considered that the TFs associated with these phenotypes

were STAT1 and NF κ B [9, 10]. The activation of at least one of these TFs is implicated with the secretion of cytokines that eliminate the possibility of tumor cells to thrive and enhance a pro-inflammatory condition [11, 12]. M2 activation has been shown to be associated with pro-tumorigenic outcomes. The key TF implicated in M2a Th2 response and profibrotic is STAT6 [13, 14]. STAT6, at the same time, can inactivate the functions of NF κ B and STAT1 through SOCS1, avoiding the M1 phenotype. The activation of the M2b macrophage is quite complex, with the inclusion of immune complexes (like immunoglobulin G (IgG)) and interleukin-1 receptors (IL1-R) (for example IL1- β) [15, 16]. The M2b macrophage has the ability to secrete not only anti-inflammatory cytokines but pro-inflammatory cytokines [17, 18]. The M2c macrophage emerges from the stimulation of IL-10 (the most important cytokine with an anti-inflammatory capacity and associated with bad prognosis in cancer [19, 20]). STAT3 is the condition for the anti-inflammatory capacity and inhibitor of the secretion of pro-inflammatory cytokines [21]. Finally, the M2d macrophage is activated via a co-stimulation of adenosines and TLR4, as well as the activation of HIF1- α [22, 23]. This macrophage is implicated in processes like angiogenesis and tumor progression, which is why they are also known as tumor-associated macrophages [23, 24]. The full description and characterization of the network used in this work is in [6]. The list of Boolean attractors and their classification in macrophage states can be reviewed in the supplementary material. The epigenetic landscape was built to apply a method that reduces the number of variables to a bi-dimensional map, in this case we used the distributed stochastic neighbor embedding algorithm (t-SNE). For the depth of the valley of each of the 13 phenotypes we used the value of the basin of attraction.

First The attractors obtained after the simulation were labeled based on the macrophage phenotype reported in the literature.

Stochastic epigenetic model

We define the potential field on the plane $(u, v) \in \mathbb{R}^2$ determined by the epigenetic landscape in the following way,

Table 1 Macrophage phenotypes used to name each attractor

Phenotype	Activated transcription factors/external components	Reviewed literature
M0	None	
M1	Activation of NF κ B, STAT1 or TNF- α and AP1	[10, 25]
M2a	Activation of IL4 and STAT6	[21, 26]
M2b	Activation of AP1 or ERK	[27]
M2c	Activation of IL10 and STAT3	[23]
M2d	Activation of TLR4 and A2a or HIF1A	[28]

$$F(u, v) = \min \left\{ a_1 \left[(u - u_1)^2 + (v - v_1)^2 \right], \right. \\ \left. a_2 \left[(u - u_2)^2 + (v - v_2)^2 \right], \dots, \right. \\ \left. a_n \left[(u - u_n)^2 + (v - v_n)^2 \right] \right\}, \quad (1)$$

where $(u_1, v_1), (u_2, v_2), \dots, (u_n, v_n)$ are the centers of the basins each corresponding to a different macrophage phenotype and a_1, a_2, \dots, a_n define the size of each basin; we obtain these quantities using the method described in Sect. 2.1 (see Fig. 2).

We study the evolution of our system in the epigenetic potential (1) and under the influence of random perturbations through the following stochastic reaction-diffusion model:

$$dx(t) = (Ax(t) + a(x(t)))dt + dW(t) \quad \text{in } (0, T], \\ x(0) = x_0, \quad (2)$$

with

$$x(t, \xi) = \begin{pmatrix} u(t, \xi) \\ v(t, \xi) \end{pmatrix}, A = \begin{pmatrix} d_1 \frac{\partial^2}{\partial \xi^2} \\ d_2 \frac{\partial^2}{\partial \xi^2} \end{pmatrix},$$

$$a(x(t))(\xi) = \begin{pmatrix} \tilde{f}(u(t, \xi), v(t, \xi)) \\ \tilde{g}(u(t, \xi), v(t, \xi)) \end{pmatrix},$$

$$W(t) = \begin{pmatrix} \sigma_1 W_1(t) \\ \sigma_2 W_2(t) \end{pmatrix},$$

where $\tilde{f} = -\partial F(u, v)/\partial u$, $\tilde{g} = -\partial F(u, v)/\partial v$, F is given by the mollification of (1), W_1 and W_2 are independent Wiener processes, $\xi \in \mathcal{O} \subset \mathbb{R}$ (with appropriate boundary conditions) and $d_1, d_2, \sigma_1, \sigma_2 > 0$ (constants). We will focus on the case $\sigma_1 = \sigma_2 = \sigma > 0$; we will refer to σ as the noise magnitude. As shown in [29], our model has a gradient flow structure for the epigenetic potential (in an appropriate infinite dimensional space). We study all the necessary mathematical results for the stochastic system (2) in [29], relying heavily on the infinite dimensional results of stochastic analysis, ergodic theory, large deviations, and stochastic optimal control. We also present the details of our stochastic numerical method in [29]. We emphasize the relevance of our rigorous mathematical results as the main corroboration of our computational observations.

We also mention that our model may consider Gaussian white or colored noise. White noise is a random signal having equal intensity at different frequencies (constant power spectral density), whereas colored noise has particular frequencies that are more prominent. Colored noise may be convenient for the TME since some molecular signals (identified with particular frequencies) may be more intense (prominent) than others. On the other hand,

colored noise is usually easier to handle than white noise (theoretically and computationally). Moreover, we study the effect of individual molecular signals (in a noiseless, ideal environment) through the boolean network model in [6, 7] (we include details in Sect. 3 for completeness), which is the basis for the stochastic model of this manuscript. In our stochastic system, introducing individual molecular signals requires the addition of controls, which we study in detail in [29]; in particular, we analyze the situation where such controls directly influence (and get perturbed by) the noise (diffusion) term, not only the drift.

We remark on the significance of the epigenetic potential (shown in Fig. 2) in our study: it encapsulates the relevant biological information for our system. Hence, we have stored the data and code necessary to obtain such potential in a repository (see Data Availability Statement) along with the Python code for the evolution of the stochastic epigenetic system.

Results

Boolean network model

As indicated in Sect. 2.2, our stochastic model departs from studying individual molecular signals in a (noiseless) ideal environment through a boolean network system [6, 7]. With this boolean system, we investigated how modulating transcription factors or external cues influence the stability of macrophage phenotypes. Sustained activation of AP-1, STAT1, or NF κ B consistently promoted hybrid macrophages with tumoricidal (M1) capabilities. Activation of AP-1 and STAT1 eliminated purely pro-tumoral phenotypes and reduced anti-tumoral ones by 20%, shifting the tumor microenvironment toward elimination (Fig. 1A). Similarly, persistent NF κ B activation balanced tumor elimination and tissue recovery by secretion of cytotoxic interleukins and interferons (Fig. 1A).

Conversely, continuous expression of HIF1- α or TGF- β eradicated pure M1 macrophages and reduced hybrids with M1 traits, fostering malignant macrophage behaviors. HIF1- α decreased anti-tumoral phenotypes by 22% and pro-tumoral ones by 40%, while TGF- β had similar effects, highlighting the need to minimize their presence in the tumor microenvironment. Modulating the balance toward anti-tumoral phenotypes may mitigate TGF- β activity.

Knocking out transcription factors also revealed key effects on phenotype stability (Fig. 1B). Eliminating Fra-1 slightly increased the tumoricidal M1 and hybrid M1M2b phenotypes without affecting M2d, enhancing tumor eradication potential. Knocking out HIF1- α increased tumoricidal phenotypes and raised pro-tumoral ones by 36% in wild-type macrophages (Fig. 1B), necessitating a coordinated immune response with




Fig. 1 Heat Map of Transcription Factor Overexpression and Knockout (based on Fig. 3 [6]). **A** Heat map showing the effects of transcription factor overexpression on macrophage polarization. **B** Heat map illustrating the impact of transcription factor knockouts on macrophage polarization. Green regions represent attractors with an increased basin size following the perturbation, while red regions denote those with a decreased basin size. Black indicates attractors with minimal changes in basin size compared to the wild-type (WT) after perturbation. Gray areas represent attractors present in the WT that disappear upon perturbation

gamma receptor activation and IFN- γ release. Interestingly, this knockout also resulted in pure M2a and M2c phenotypes, which favor tumor progression. STAT3 knockout reduced tumor-eradicating phenotypes and anti-tumoral hybrids by 33% but decreased pro-tumoral phenotypes (M2c) by 63%, mediated via NF κ B activation. In contrast, STAT6 knockout did not affect anti-tumoral phenotypes but reduced the basin of attraction. The M2c phenotype, which secretes IL-10, fosters tumor evasion and metastasis. Experimental evidence supports the role of STAT3 and STAT6 in reducing tumor growth and metastasis in breast and lung cancer models [26, 30].

Stochastic epigenetic model and the relevance of random perturbations in the tumor microenvironment

Using our stochastic system, we compared the behavior of all types of macrophages immersed in different values of (the magnitude of the) noise (σ); this noise represents the




Fig. 2 Macrophages' epigenetic potential (Waddington's landscape) in 3D (top) and the corresponding contour representation (bottom). The figure at the bottom shows the locations of the thirteen types of macrophages (phenotypes) in the epigenetic landscape, where each dot is the center of a phenotype, and the contours represent the depth of each phenotype (dark blue corresponds to the deepest region). In what follows, we use the contour representation of the epigenetic potential

environmental fluctuations in a TME. Lower noise values in our study will represent a starting TME, corresponding to a nascent tumor still hijacking the processes in its surroundings. Meanwhile, as the noise increases, the microenvironment evolves to a much more complicated scenario, where the tumor is already thriving with the surroundings hijacked into a tumor-supportive microenvironment. Figure 2 depicts the locations of the thirteen types of macrophages (phenotypes) in the epigenetic landscape, where each dot is the center of a phenotype, and the contours represent the depth of each phenotype (dark blue corresponds to the deepest region). These two-dimensional projections of each phenotype and the associated contours represent attractors determined using a boolean approach from [6]. We can observe 5 clusters, where 4 have macrophages with a tumor-supportive

function, and only one cluster has a tumor suppressor function (M1 and M1M2d).

In the following simulations, we used different starting points in the landscape of the TAMs to evaluate how the noise could affect the dynamics (epigenetic state) of the adaptation of the macrophages to distinct stages of a tumor microenvironment. We ran our simulations with different noise magnitudes but for the same time interval. The first scenario starts with an M1 macrophage phenotype associated with the capacity to eliminate tumor cells. Figure 3 shows that the macrophage remains in the basin of attraction of M1 for the entire time interval of the simulations. It is significant to notice the effect of the magnitude of the noise in the distribution of the epigenetic state of the macrophage: as the magnitude increases, the region within the M1 basin corresponding to the state of the macrophage (white area) gets more spread out. We proved in [29] that this distribution converges to a location concentrated at the basin's center (yellow dot) as the noise decreases, showing the expected behavior in a noiseless controlled environment. The situation changes drastically in Fig. 4: for this noise magnitude (a

more advanced stage of the TME), the macrophage remains for a short time in the M1 basin until it suddenly jumps to the M1M2d basin and, as time progresses, the macrophage keeps moving through the epigenetic landscape until reaching the basing corresponding to the M2aM2d phenotype. We call these transitions (entirely driven by the TME) noise-induced polarization. Although our model is stochastic with a driving random component (the TME), we can estimate, in a rigorous mathematical setting with probability 1, the exit time and the transition points in Fig. 4. This is relevant since these transitions can only occur in the so-called mountain passes of the epigenetic landscape, showing that even though the environmental epigenetic fluctuations drive the system, also the genetic component (encapsulated in the epigenetic landscape) determines the time and region of the transitions (polarizations, epigenetic mutations). We also remark that the results in Fig. 3 do not indicate that, for lower noise magnitudes, there will not be a transition (polarization). We can prove, with probability 1, that such transitions will occur. However, it will be complicated to observe them computationally: the transition time becomes larger since it depends




Fig. 3 Evolution of the epigenetic state of a macrophage (in white) starting at the M1 phenotype center, up to t units of time, and subjected to different noise magnitudes, σ , representing the stages of the

TME: the higher the value of σ , the more advanced the tumor is. The noise (a Brownian process) represents the molecular signals in the TME




Fig. 4 Evolution of the epigenetic state of a macrophage (in white) starting at the M1 phenotype center showing the noise-induced polarization into protumoral phenotypes due to the TME. Each plot shows the system's dynamics up to t units of time, with fixed $\sigma = 0.27$

inversely on the noise magnitude. These results may also show the possible relevance of our methodology in the study of aging [31] and diseases like Alzheimer's [32].

Despite having the compartment M2d implicated in the secretion of components associated with tumor promotion, M1M2d has a role in wound healing [33, 34]. Wound healing is a significant counterbalance provided by the secretion of inflammatory components from the M1 phenotype. As we

mentioned before, Fig. 4 shows that the M1M2d macrophage finally polarizes into the cluster that holds two tumor-supportive phenotypes (M2aM2d and M2aM2bM2d); in this scenario, the macrophage will only secrete components that will benefit a microenvironment that will allow the tumor to grow.

Macrophages enter the location where the tumor resides as monocytes circulating in the blood. Figures 5,

6 show the simulations where we were interested in studying how the monocyte responds to the perturbation from the TME by increasing the noise. We can observe that the monocyte polarizes into an M2d macrophage despite a low noise value. As the noise and the time increase, the monocyte polarizes into a macrophage with an M2 phenotype implicated in a tumor-supportive role, finalizing in the M2bM2d phenotype, which favors tumor progression, metastasis and immune evasion [6, 7]. Finally, Figs. 7, 8 show our results starting from the hybrid phenotype M1M2bM2cM2d.

Our results show that macrophages can be associated with a poor prognosis in many types of cancer. Therefore, a therapy involving macrophages has to consider this situation and requires an additional mechanism to ensure the appropriate epigenetic stability; we will discuss this situation in detail in the next section.

Discussion

Our model shows that the influence of the TME on a therapy involving macrophages can render it ineffective and even benefit the tumor progression. Since the TME produces a noise-induced polarization of macrophages, we need an additional mechanism to promote epigenetic stability. [35] shows the unique role of p53 in the regulation of M2 macrophage's polarization, in particular, a function for the p53/MDM2/c-MYC axis as a physiological 'brake' to the M2 polarization process; p53 is the first transcription factor reported to suppress M2 macrophage's polarization. On the other hand, [36] demonstrates that increased p53 expression in TAMs induces canonical p53-associated functions such as senescence and activation of a p53-dependent senescence-associated secretory phenotype. This was linked with decreased expression of proteins associated with M2 polarization by TAMs. [36] also presents a clinical trial in patients with solid tumors combining APR-246 (which increases p53 signaling) with pembrolizumab, showing




Fig. 5 Evolution of the epigenetic state of a macrophage (in white) starting at the M0 phenotype center (monocyte), up to t units of time, and subjected to different noise magnitudes, σ , representing the stages

of the TME: the higher the value of σ , the more advanced the tumor is. The noise (a Brownian process) represents the molecular signals in the TME




Fig. 6 Evolution of the epigenetic state of a macrophage (in white) starting at the M0 phenotype center showing the noise-induced polarization into protumoral phenotypes due to the TME. Each plot shows the system's dynamics up to t units of time, with fixed $\sigma = 0.20$

that biospecimens from select patients had suppression of M2-polarized myeloid cells and an increase in T-cell proliferation, leading to suggest that increasing p53 expression in TAMs 'reprograms' the TME to augment the response to immune checkpoint blockade.

The previous observations, along with our results about noise-induced polarization, highly suggest that any immunotherapy involving macrophages should include a mechanism

capable of increasing p53 signaling, like APR-246 (eprenetapopt), to promote the appropriate epigenetic stability; see Fig. 9. We also mention the review by Levine and Berger [37] that discusses the cross-talk between p53 and epigenetic programs: p53 not only enforces the stability of the genome by preventing genetic alterations in cells but also plays a significant role in regulating the epigenetic changes that occur in cells.




Fig. 7 Evolution of the epigenetic state of a macrophage (in white) starting at the M1M2bM2cM2d phenotype center, up to t units of time, and subjected to different noise magnitudes, σ , representing the

stages of the TME: the higher the value of σ , the more advanced the tumor is. The noise (a Brownian process) represents the molecular signals in the TME

Only targeting macrophage polarization as a treatment against cancer may not be enough, mainly because of how susceptible they are to the TME. Pembrolizumab, an immune checkpoint inhibitor targeting the PD-1 receptor, has shown considerable efficacy in activating T cells within the TME. Although its primary mechanism is aimed at T cells, emerging evidence suggests it may also affect macrophage polarization and function, which are crucial factors in the immune response to cancer. For example, in [38], the authors demonstrate that macrophages can express PD-1, particularly in the TME, where macrophages exhibit an exhausted phenotype, leading to decreased phagocytic activity and altered cytokine production. Inhibition of PD-1 on macrophages could rejuvenate their phagocytic abilities and shift their polarization towards a more pro-inflammatory phenotype. Because of the action of this drug on T cells, it could lead to the production of interferon-gamma, a cytokine that can induce M1 polarization of macrophages, supporting a more robust anti-tumor response [39, 40]. Furthermore, blocking PD-1 might alter the cytokine profile within the TME, reducing immunosuppressive cytokines (IL-10) that

favor M2 polarization and increasing the cytokines that promote M1 polarization [41, 42].

On the other hand, APR-246 is a reactivator of mutant p53 protein that induces apoptosis and inhibits tumor growth in tumor cells; this restored p53 function can influence the TME, potentially altering the secretion of cytokines and chemokines that regulate macrophage behavior [43]. Moreover, APR-246 could indirectly affect macrophages by modulating the expression of genes involved in the immune response. For instance, p53 can influence the expression of various cytokines and surface molecules that may affect macrophage recruitment and polarization [36, 44]. Finally, APR-246 might promote a pro-inflammatory environment by enhancing p53's role in apoptosis and cell-cycle arrest in tumor cells; this could lead to increased tumor cell death, releasing tumor antigens and associated danger signals that could shift macrophage polarization towards a pro-inflammatory, anti-tumoral M1 phenotype [45].

The combination therapy between pembrolizumab, APR-246, and macrophages opens up new avenues for cancer therapy, particularly in understanding how




Fig. 8 Evolution of the epigenetic state of a macrophage (in white) starting at the M1M2bM2cM2d phenotype center showing the noise-induced polarization. Each plot shows the system's dynamics up to t units of time, with fixed $\sigma = 0.25$




Fig. 9 The effect of p53 on the epigenetic evolution of macrophages in a TME. Left: p53 stabilizes the epigenetic M1 state. Right: in the absence of an epigenetic stabilizer, the macrophage polarizes into a protumoral state

immune checkpoint inhibitors can modify the tumor microenvironment to promote more robust anti-tumor responses. A current clinical trial evaluates the combination of both drugs and how they affect the TME and the immune checkpoint inhibitors [45, 46]. The

potential reprogramming of macrophages could amplify the efficacy of pembrolizumab and possibly improve outcomes in cancers where macrophages play a significant role in tumor progression and immune evasion. Further research is necessary to delineate how pembrolizumab

and similar drugs affect macrophage polarization in different types of cancers in conjunction with other treatments. These findings could lead to new combination therapies that target multiple cells and pathways within the immune system for a more comprehensive approach to cancer immunotherapy. An appropriate understanding of these mechanisms requires more focused studies, which could lead to more effective strategies in immunoncology, enhancing the therapeutic benefits of drugs like pembrolizumab in various cancer types.

Our stochastic optimal control model in [29] shows that the effect of p53 can be considered as a control on the drift of the system. Moreover, as long as the macrophages stay in an antitumoral state, the noise in the TME should be reduced as a consequence of the macrophages attacking the cancer cells, which will also help with the epigenetic stability (see Fig. 3); we can study this phenomenon with our model through a control in the diffusion (noise) term, which can change with the state of macrophages, capturing the impact of macrophages on the tumor as they polarize from M1 to M2 states. On the other hand, M1 macrophages augment the response to immune checkpoint blockade and increase T-cell proliferation: since the interaction of these different agents is relevant to describe the tumor, we believe that our model can capture the complexity of the TME more accurately by considering, in addition, the theory of (stochastic evolutionary) games with predator–prey structure including many species (macrophages, T cells, cancer cells, etc). In this case, we could study the population of the different species, their interactions, their epigenetic states, the influence of hypoxia, toxicity, nutrients, external controls (like APR-246, pembrolizumab, epidrugs), and the effect these factors have on the TME: notice that in this ecosystem the species may mutate and change their roles (phenotypes) drastically in a “short-term”; cf. evolutionary game theory [47], evolutionary invasion analysis (adaptive dynamics) [48]. We believe these aspects are fundamental in determining an appropriate immunotherapy for cancer.

Author contributions The three authors contributed to initiating the study and overseeing the research activities. Jesus Sierra was involved in the formal analysis, investigation, methodology, software, and validation. Ugo Avila was involved in conceptualization, investigation, and verification. Pablo Padilla contributed to the formal analysis, methodology, validation, and project administration. The three authors contributed to the manuscript’s writing, review, and editing.

Funding No funding was received for conducting this study.

Data availability We have archived our Python code on Zenodo (<https://zenodo.org/records/13314201>). We perform extensive stochastic and numerical analysis of our epigenetic model in [29]. Data related to the epigenetic potential can be found at (<https://github.com/resendislab/M1-M2-Macrophage-Polarization>).

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in cancer therapy. *Nat Rev Drug Discov* 21(11):799–820
2. Pan Y, Yu Y, Wang X, Zhang T (2020) Tumor-associated macrophages in tumor immunity. *Front Immunol* 11:583084
3. Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X, Zhao Y, Wei Y (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. *PLoS One* 7(12):e50946
4. Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, Taiana E, Neri A, Bomben R, Gentile M et al (2021) Antitumor effects of PRIMA-1 and PRIMA-1Met (APR246) in hematological malignancies: still a mutant p53-dependent affair? *Cells* 10(1):98
5. Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O’Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ et al (2019) Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. *Sci Transl Med* 11(479):eaat1500
6. Avila-Ponce de León U, Vázquez-Jiménez A, Matadamas-Guzman M, Pelayo R, Resendis-Antonio O (2021) Transcriptional and microenvironmental landscape of macrophage transition in cancer: a boolean analysis. *Front Immunol* 12:642842
7. Avila-Ponce de León U, Vázquez-Jiménez A, Matadamas-Guzmán M, Resendis-Antonio O (2022) Boolean modeling reveals that cyclic attractors in macrophage polarization serve as reservoirs of states to balance external perturbations from the tumor microenvironment. *Front Immunol* 13:1012730
8. Selig M, Poehlman L, Lang NC, Völker M, Rolaußs B, Hart ML (2024) Prediction of six macrophage phenotypes and their IL-10 content based on single-cell morphology using artificial intelligence. *Front Immunol* 14:1336393
9. Kawasaki T, Kawai T (2014) Toll-like receptor signaling pathways. *Front Immunol* 5:112681
10. Malyshev I, Malyshev Y (2015) Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage “switch” phenotype. *Biomed Res Int* 2015:341308
11. Orecchioni M, Ghosheh Y, Pramod AB, Ley K (2019) Macrophage polarization: different gene signatures in M1 (LPS+) vs. classically and M2 (LPS-) vs. alternatively activated macrophages. *Front Immunol* 10:451543

12. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. *Trends Immunol* 33(3):119–126
13. Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, McEvoy J, Roussel MF, Dyer MA, Qualls JE et al (2015) TNF counterbalances the emergence of M2 tumor macrophages. *Cell Rep* 12(11):1902–1914
14. Piersma B, Hayward MK, Weaver VM (2020) Fibrosis and cancer: a strained relationship. *Biochim Biophys Acta Rev Cancer* 1873(2):188356
15. Bally APR, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, Boss JM (2015) NF- κ B regulates PD-1 expression in macrophages. *J Immunol* 194(9):4545–4554
16. Wang LX, Zhang SX, Wu HJ, Rong XL, Guo J (2019) M2b macrophage polarization and its roles in diseases. *J Leukoc Biol* 106(2):345–358
17. Ohama H, Asai A, Ito I, Suzuki S, Kobayashi M, Higuchi K, Suzuki F (2015) M2b macrophage elimination and improved resistance of mice with chronic alcohol consumption to opportunistic infections. *Am J Pathol* 185(2):420–431
18. Rhee I (2016) Diverse macrophages polarization in tumor microenvironment. *Arch Pharmacol Res* 39(11):1588–1596
19. Wang H, Wang L, Chi PD, Wang WD, Chen XQ, Geng QR, Xia ZJ, Lu Y (2016) High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. *Br J Cancer* 114(4):463–468
20. Zhao S, Wu D, Wu P, Wang Z, Huang J (2015) Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis. *PLoS One* 10(10):e0139598
21. Hutchins AP, Diez D, Miranda-Saavedra D (2013) The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. *Brief Funct Genomics* 12(6):489–498
22. Anders CB, Lawton TMW, Smith HL, Garret J, Doucette MM, Ammons MCB (2022) Use of integrated metabolomics, transcriptomics, and signal protein profile to characterize the effector function and associated metabotype of polarized macrophage phenotypes. *J Leukocyte Biol* 111(3):667–693
23. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbat M, Jeannin P (2009) Interferon- γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. *Int J Cancer* 125(2):367–373
24. Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X (2021) Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. *Front Immunol* 12:613530
25. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. *J Leukoc Biol* 86(5):1065–1073
26. Binnemars-Postma K, Bansal R, Storm G, Prakash J (2018) Targeting the stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. *FASEB J* 32(2):969–978
27. Seager RJ, Hajal C, Spill F, Kamm RD, Zaman MH (2017) Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. *Converg Sci Phys Oncol* 3(3):034002
28. O'Carroll C, Fagan A, Shanahan F, Carmody RJ (2014) Identification of a unique hybrid macrophage-polarization state following recovery from lipopolysaccharide tolerance. *J Immunol* 192(1):427–436
29. Padilla-Longoria P, Sierra J (2024) On a stochastic PDE model for epigenetic dynamics. *arXiv preprint arXiv:2401.03596*
30. Iriki T, Ohnishi K, Fujiwara Y, Horlad H, Saito Y, Pan C, Ikeda K, Mori T, Suzuki M, Ichiyasu H et al (2017) The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation. *Lung Cancer* 106:22–32
31. Wang HT, Xiao FH, Gao ZL, Guo LY, Yang LQ, Li GH, Kong QP (2024) Methylation entropy landscape of Chinese long-lived individuals reveals lower epigenetic noise related to human healthy aging. *Aging Cell* 23:e14163
32. Sharma VK, Mehta V, Singh TG (2020) Alzheimer's disorder: epigenetic connection and associated risk factors. *Curr Neuroparmacol* 18(8):740–753
33. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F et al (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF- κ B and enhanced IRF-3/STAT1 activation). *Blood* 107(5):2112–2122
34. Zhang Q, Sioud M (2023) Tumor-associated macrophage subsets: shaping polarization and targeting. *Int J Mol Sci* 24(8):7493
35. Li L, Ng DSW, Mah WC, Almeida FF, Rahmat SA, Rao VK, Leow SC, Laudisi F, Peh MT, Goh AM et al (2015) A unique role for p53 in the regulation of M2 macrophage polarization. *Cell Death Differ* 22(7):1081–1093
36. Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, Samaan F, Ho YJ, Campesato LF, Mangarin L et al (2022) Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. *The Journal of Clinical Investigation* 132(18):e148141
37. Levine AJ, Berger SL (2017) The interplay between epigenetic changes and the p53 protein in stem cells. *Genes Dev* 31(12):1195–1201
38. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D et al (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* 545(7655):495–499
39. Dhupkar P, Gordon N, Stewart J, Kleinerman ES (2018) Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. *Cancer Med* 7(6):2654–2664
40. Tumei PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* 515(7528):568–571
41. Ngiew SF, Young A, Jacquelinot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015) A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. *Can Res* 75(18):3800–3811
42. Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C (2023) Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. *Mol Cancer* 22(1):58
43. Lehmann S, Bykov VJN, Ali D, Andr n O, Cherif H, Tidefelt U, Uggl  B, Yachnin J, Juliusson G, Moshfegh A et al (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. *J Clin Oncol* 30(29):3633–3639
44. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* 92(6):725–734
45. Tessoulin B, Descamps G, Moreau P, Ma ga S, Lod  L, Godon C, Marionneau-Lambot S, Oullier T, Le Gouill S, Amiot M et al (2014) PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. *Blood* 124(10):1626–1636
46. Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A et al (2022) Phase Ib study of eprentapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. *ESMO Open* 7(5):100573
47. Vincent TL, Brown JS (2005) Evolutionary game theory, natural selection, and Darwinian dynamics. Cambridge University Press, Cambridge

48. Dercole F, Rinaldi S (2008) Analysis of evolutionary processes: the adaptive dynamics approach and its applications. Princeton

University Press, Princeton

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.